70名患有帕金森病的帕金森病患者的膀过活症状的药物疗效
Chunsong Jia1, Xin Cui1, Tongwen Ou1
1Department of Urology, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.
Translational andrology and urology
|February 26, 2024
概括
托尔特罗丁和坦苏洛辛在帕金森病 (PD) 患者中有效治疗过度活性膀 (OAB) 症状. 然而,在许多人治疗后,夜尿和急迫症仍然存在.
科学领域:
- 神经学 神经学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
背景情况:
- 在帕金森病 (PD) 中过度活性膀 (OAB) 管理具有重大临床挑战.
- 研究PD患者OAB的有效药理干预措施对于改善生活质量至关重要.
研究的目的:
- 评估tolterodine和tamsulosin在患有帕金森病的患者中管理过活膀症状的疗效.
- 评估这些药物对尿路症状得分和患者报告结果的影响.
主要方法:
- 对187名患有OAB症状的帕金森病患者进行了查.
- 招募了70名患者,他们接受了托尔特罗丁,坦苏洛辛或其组合的治疗.
- 国际前列腺症状评分 (IPSS) 和过度活性膀症状评分 (OABSS) 在治疗前后进行评估.
主要成果:
- 在治疗后的IPSS存储症状和OABSS中观察到显著改善 (P<0.01).
- 托尔特罗丁,坦苏洛辛和组合疗法对OAB症状严重程度产生了积极影响.
- 尽管情况有所改善,但40%的患者仍然出现了中度的尿路症状,夜尿和急性仍然普遍存在.
结论:
- 托尔特罗丁和/或坦苏洛辛可显著改善帕金森病患者过度活动膀的症状.
- 即使在使用这些药物治疗后,夜和急性仍然是常见的和具有挑战性的症状.
相关概念视频
01:24Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
01:15Parkinson's Disease: Overview
546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546
01:28Drug Therapy
44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
44
01:26Cholinergic Antagonists: Therapeutic Uses
749
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
749
01:17Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
319
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
319